Metrics as of 10/13/2026, 06:53 PM (Berlin time), refresh in progress.
Prothena Stock
Prothena Corporation plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Ireland
- CEO
- Gene G. Kinney
- Employees
- 67
- Market cap
- $442 M
- IPO
- 20/12/2012
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the…
Prothena stock: price history
1D
+1.0%
1W
-0.5%
1M
-4.7%
6M
-22.0%
YTD
-11.6%
1Y
-16.6%
2Y
-51.3%
5Y
-86.7%
10Y
-84.2%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~12% stronger price swings than usual
Ask the agents about Prothena
Analyst assessment of Prothena
PRICE TARGET LOW
US$30.00
CONSENSUS
US$30.00
MEDIAN
US$30.00
PRICE TARGET HIGH
US$30.00
0
STRONG BUY
20
BUY
6
HOLD
2
SELL
0
STRONG SELL
28
TOTAL · Buy
As of: 08/05/2026
Prothena stock metrics
P/E
-10.16
P/B
1.53
EV/EBITDA
-3.75
RETURN ON EQUITY
-6.5%
NET MARGIN
-1,839.9%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.9%
FLOAT SHARES
46,546,444
AVG. DAILY VOLUME (30D)
508,602
Insider transactions (SEC)
SCULLY WILLIAM P
SCULLY WILLIAM P
SCULLY WILLIAM P
SCULLY WILLIAM P
SCULLY WILLIAM P
Institutional holders
Comparable stocks
Frequently asked questions about Prothena stock
What does Prothena do?
Prothena Corporation plc is a company in the Healthcare sector, Biotechnology industry, headquartered in Ireland.
The CEO is Gene G. Kinney, the company employs around 67 people.
The IPO was on 20/12/2012; the stock trades on NASDAQ under the ticker PRTA.
What do analysts say about Prothena stock?
28 analysts rate the stock, the consensus is Buy (as of 08/05/2026).
The average price target is US$30.00, ranging from US$30.00 to US$30.00, with a median of US$30.00.
This is an external assessment, not a statement by Market Jury.
When does Prothena report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 12% stronger than usual.
Does Prothena pay a dividend?
No, Prothena currently does not pay a dividend.
Which stocks are comparable to Prothena?
Comparable stocks include Jazz Pharmaceuticals, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Prothena stock analyzed?
Clicking "Analyze stock" lets five strategies assess Prothena against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.